Literature DB >> 26837939

Successful treatment of Sydenham's chorea with intravenous immunoglobulin.

Nienke Anne Boersma1, Herman Schippers2, Taco Kuijpers3, Jojanneke Heidema4.   

Abstract

We present a case of a 10-year-old girl diagnosed with Sydenham's chorea. Despite treatment with haloperidol and valproic acid for 2 weeks and antibiotics for 5 days, her symptoms continued to worsen. She became severely impaired in daily functioning, as she could barely speak or walk, experienced major feeding difficulties and required help with all daily activities. She was treated with intravenous immunoglobulin (IVIG). Within 4 days, her symptoms started to improve and after 1-month she had fully recovered. This case reminds us that Sydenham's chorea can result in major functional impairment. There is some evidence on the beneficial effect of IVIG in the treatment of Sydenham's chorea, as is evident in our case. Therefore, IVIG should be considered as a treatment option in patients with severe chorea. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26837939      PMCID: PMC4746543          DOI: 10.1136/bcr-2015-211673

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  19 in total

1.  Randomized double-blind study with prednisone in Sydenham's chorea.

Authors:  José A Paz; Clovis A A Silva; Maria J Marques-Dias
Journal:  Pediatr Neurol       Date:  2006-04       Impact factor: 3.372

2.  THE NATURAL HISTORY OF SYDENHAM'S CHOREA. REVIEW OF THE LITERATURE AND LONG-TERM EVALUATION WITH EMPHASIS ON CARDIAC SEQUELAE.

Authors:  A M ARON; J M FREEMAN; S CARTER
Journal:  Am J Med       Date:  1965-01       Impact factor: 4.965

3.  Treatment of sydenham chorea with intravenous immunoglobulin.

Authors:  Kathleen Walker; Anita Brink; John Lawrenson; Wendy Mathiassen; Jo M Wilmshurst
Journal:  J Child Neurol       Date:  2011-08-24       Impact factor: 1.987

4.  An update on the treatment of Sydenham's chorea: the evidence for established and evolving interventions.

Authors:  Kathleen G Walker; Jo M Wilmshurst
Journal:  Ther Adv Neurol Disord       Date:  2010-09       Impact factor: 6.570

5.  Rheumatic chorea in northern Australia: a clinical and epidemiological study.

Authors:  J R Carapetis; B J Currie
Journal:  Arch Dis Child       Date:  1999-04       Impact factor: 3.791

6.  UFMG Sydenham's chorea rating scale (USCRS): reliability and consistency.

Authors:  Antônio Lúcio Teixeira; Débora P Maia; Francisco Cardoso
Journal:  Mov Disord       Date:  2005-05       Impact factor: 10.338

7.  Persistence of acute rheumatic fever in the intermountain area of the United States.

Authors:  L G Veasy; L Y Tani; H R Hill
Journal:  J Pediatr       Date:  1994-01       Impact factor: 4.406

8.  Rheumatic chorea: relationship to systemic manifestations and response to corticosteroids.

Authors:  Adrianne R Walker; Lloyd Y Tani; Joel A Thompson; Sean D Firth; L George Veasy; James F Bale
Journal:  J Pediatr       Date:  2007-08-24       Impact factor: 4.406

Review 9.  Acute and chronic chorea in childhood.

Authors:  Donald L Gilbert
Journal:  Semin Pediatr Neurol       Date:  2009-06       Impact factor: 1.636

Review 10.  Sydenham Chorea and PANDAS in South Africa: Review of Evidence and Recommendations for Management in Resource-Poor Countries.

Authors:  Kathleen G Walker; Petrus J de Vries; Dan J Stein; Jo M Wilmshurst
Journal:  J Child Neurol       Date:  2014-09-16       Impact factor: 1.987

View more
  2 in total

Review 1.  Treatment of Sydenham's Chorea: A Review of the Current Evidence.

Authors:  Shannon L Dean; Harvey S Singer
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2017-06-01

Review 2.  Therapeutic aspects of Sydenham's Chorea: an update.

Authors:  Greta Depietri; Niccolo Carli; Attilio Sica; Domenico Oliviero; Giorgio Costagliola; Pasquale Striano; Alice Bonuccelli; Flavia Frisone; Diego Peroni; Rita Consolini; Thomas Foiadelli; Alessandro Orsini
Journal:  Acta Biomed       Date:  2022-03-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.